US FDA to Review Heart Risks of Novartis Corporation’s Parkinson’s Drug

August 20, 2010 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

WASHINGTON Aug 20 (Reuters) - The U.S. Food and Drug Administration said on Friday it will examine the potential heart risks of Novartis AG's (NOVN.VX) Parkinson's drug Stalevo, a combination of two treatments for the debilitating brain disease.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Postmarket research

Food and Drug Administration (FDA)